Responses
EULAR 2014: Scientific Abstracts
Poster Presentations. Vasculitis
FRI0474 The Three-Year Outcome of Infliximab (IFX), an Anti-TNF-α Antibody, in Patients with Refractory Intestinal-BehÇEt's Disease (BD)
Compose a Response to This Article
Other responses
No responses have been published for this article.